A Phase 2 Trial of Protein Kinase C Iota Inhibition With the Combination of Auranofin and Sirolimus in Patients With Recurrent Ovarian Cancer
As prescribed here, auranofin and sirolimus manifested no antineoplastic activity in patients with recurrent high-grade serous ovarian cancer that expressed PKCι.
Authors
- Matthew Stephen Block (ORCID: https://orcid.org/0000-0001-5692-4219)
- Nicole R. Murray (ORCID: https://orcid.org/0000-0002-6833-8273)
- Nathan R. Foster (ORCID: https://orcid.org/0000-0002-2874-1295)
- Erik Asmus
- Andrea Wahner Hendrickson
- Aminah Jatoi (ORCID: https://orcid.org/0000-0002-1081-189X)
- Alan P. Fields (ORCID: https://orcid.org/0000-0001-9529-0888)
- S. John Weroha (ORCID: https://orcid.org/0000-0002-7130-7259)
Institutions
- Mayo Clinic in Arizona (US)
- Mayo Clinic in Florida (US)
Publication Details
- Journal
- American Journal of Clinical Oncology
- Published
- 2025-10-20
- DOI
- https://doi.org/10.1097/coc.0000000000001263
- Primary Topic
- Microtubule and mitosis dynamics
- Type
- article
- Field-Weighted Citation Impact
- 0.00